Results from the Turquoise III trial show an antiviral combo cured patients with chronic hepatitis C genotype 1b infections, according to data to be released June 26 at the International Symposium on Viral Hepatitis and Liver Diseases in Berline, Germany.
Patients with chronic hepatitis C genotype 1b infections and compensated liver cirrhosis were 100% cured with a combination of anti-viral tablets taken without the addition of ribavirin, according to study results due to be presented June 26 at the 15th International Symposium on Viral Hepatitis and Liver Diseases in Berlin, Germany.
In a news release, AbbVie announced phase 3B results of the TURQUOISE-III trial of its ombitasvir/paritaprevir/ritonavir tablet, marketed as Viekirax and prescribed with dasabuvir (Exviera/AbbVie).
The drug regimen takes 12 weeks, except in genotype 1a and genotype 4 patients who should take it for 24 weeks with ribavirin.
It is not indicated for patients with severe hepatic impairment, that is, patients whose Child-Pugh score is “C”, the worst rating.
The multi-center open-label study evaluated the safety and efficacy of treatment in 60 adults with genotype 1b chronic hepatitis C infections.
According to the pharmaceutical company, genotype 1b is the most prevalent hepatitis C subtype in genotype 1.
Genotype 1 infection affects 60% of the world’s estimated 160 million people who have hepatitis C.
In the Turquoise III study, the subjects were both treatment-naïve and patients who had failed previous therapy with pegylated interferon and ribavirin.
The Viekirax drug combination is already approved in Europe for treatment of genotype 1 and genotype 4 hepatitis C infection.
Side effects include fatigue and nausea. In the Turquoise III study investigators also reported some subjects had diarrhea and headache.